Association of genetic variants with myocardial infarction in Japanese individuals with or without metabolic syndrome

Kawamiya,Toshiki; Kato,Kimihiko; Horibe,Hideki; Yokoi,Kiyoshi; Oguri,Mitsutoshi; Yoshida,Tetsuro; Fujimaki,Tetsuo; Watanabe,Sachiro; Satoh,Kei; Aoyagi,Yukitoshi; Nozawa,Yoshinori; Murohara,Toyoaki; Yamada,Yoshiji

doi:10.3892/etm.2010.147

Association of genetic variants with myocardial infarction in Japanese individuals with or without metabolic syndrome

Authors:
- Toshiki Kawamiya
- Kimihiko Kato
- Hideki Horibe
- Kiyoshi Yokoi
- Mitsutoshi Oguri
- Tetsuro Yoshida
- Tetsuo Fujimaki
- Sachiro Watanabe
- Kei Satoh
- Yukitoshi Aoyagi
- Yoshinori Nozawa
- Toyoaki Murohara
- Yoshiji Yamada
View Affiliations

Affiliations: Department of Cardiovascular Medicine, Gifu Prefectural Tajimi Hospital, Tajimi, Japan, Meito Hospital, Nagoya, and Life Science Research Center, Mie University, Tsu, Japan, Department of Cardiology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan, Department of Cardiovascular Medicine, Inabe General Hospital, Inabe, Japan, Department of Cardiology, Gifu Prefectural General Medical Center, Gifu, Japan, Department of Vascular Biology, Institute of Brain Science, Hirosaki University Graduate School of Medicine, Hirosaki, Japan, Department of Genomics for Longevity and Health, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan, Gifu International Institute of Biotechnology and Tokai Gakuin University, Kakamigahara, Japan, Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan, Department of Human Functional Genomics, Life Science Research Center, Mie University, Tsu, Japan
Published online on: September 10, 2010 https://doi.org/10.3892/etm.2010.147
Pages: 969-975

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The etiology of metabolic syndrome (MetS) is highly complex, with both genetic and environmental factors being thought to play an important role. Although MetS has been recognized as a risk factor for myocardial infarction (MI), the genetic risk for MI in individuals with or without MetS has remained uncharacterized. We examined a possible association of genetic variants with MI in individuals with or without MetS separately. The study population comprised 4,424 individuals, including 1,918 individuals with MetS (903 subjects with MI and 1,015 controls) and 2,506 individuals without MetS (499 subjects with MI and 2,007 controls). The 150 polymorphisms examined in the present study were selected by genome-wide association studies of MI and ischemic stroke with the use of Affymetrix GeneChip Human Mapping 500K Array Set. Initial screening by the Chi-square test revealed that the C→T polymorphism (rs1794429) of LRPAP1, the A→G polymorphism (rs12373237) of LAMA3 and the A→G polymorphism (rs3782257) of NCOR2 were significantly (false discovery rate of <0.05) associated with MI for individuals with MetS, and that the C→G polymorphism (rs13051704) of TFF1 was significantly related to MI for individuals without MetS. Subsequent multivariable logistic analysis with adjustment for covariates revealed that rs1794429 of LRPAP1 (recessive model; P=0.0218; odds ratio=0.71) and rs3782257 of NCOR2 (dominant model; P=0.0057; odds ratio=1.94) were significantly associated with MI among individuals with MetS, and that rs13051704 of TFF1 (additive model; P=0.0100; odds ratio=0.55) was significantly associated with MI among individuals without MetS. The genetic variants that confer susceptibility to MI differ between individuals with or without MetS. Stratification of subjects according to the presence or absence of MetS may thus be important for personalized prevention of MI based on genetic information.

View Figures

View References

1.	Alberti KG, Eckel RH, Grundy SM, et al: International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 120:1640–1645. 2009.
2.	Mohlke KL, Boehnke M and Abecasis GR: Metabolic and cardiovascular traits: an abundance of recently identified common genetic variants. Hum Mol Genet. 17:R102–R108. 2008. View Article : Google Scholar : PubMed/NCBI
3.	Lusis AJ, Attie AD and Reue K: Metabolic syndrome: from epidemiology to systems biology. Nat Rev Genet. 9:819–830. 2008. View Article : Google Scholar : PubMed/NCBI
4.	Iribarren C, Go AS, Husson G, et al: Metabolic syndrome and early-onset coronary artery disease: is the whole greater than its parts? J Am Coll Cardiol. 48:1800–1807. 2006. View Article : Google Scholar : PubMed/NCBI
5.	Espinola-Klein C, Rupprecht HJ, Bickel C, et al: Impact of metabolic syndrome on atherosclerotic burden and cardiovascular prognosis. Am J Cardiol. 99:1623–1628. 2007. View Article : Google Scholar : PubMed/NCBI
6.	Daly CA, Hildebrandt P, Bertrand M, et al: EUROPA investigators. Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: data from the EUROPA trial. Heart. 93:1406–1411. 2007. View Article : Google Scholar
7.	Lloyd-Jones D, Adams RJ, Brown TM, et al: Heart disease and stroke statistics – 2010 update: a report from the American Heart Association. Circulation. 121:e46–e215. 2010.
8.	Sattar N, Gaw A, Scherbakova O, et al: Metabolic syndrome with and without C-protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 108:414–419. 2003. View Article : Google Scholar
9.	Ridker PM, Buring JE, Cook NR, et al: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation. 107:391–397. 2003.PubMed/NCBI
10.	Kanazawa M, Yoshiike N, Osaka T, et al: Criteria and classification of obesity in Japan and Asia-Oceania. Asia Pac J Clin Nutr. 11:S732–S737. 2002. View Article : Google Scholar
11.	Yamada Y, Fuku N, Tanaka M, et al: Identification of CELSR1 as a susceptibility gene for ischemic stroke in Japanese individuals by a genome-wide association study. Atherosclerosis. 207:144–149. 2009. View Article : Google Scholar : PubMed/NCBI
12.	Fujimaki T, Kato K, Yokoi K, et al: Association of genetic variants in SEMA3F, CLEC16A, LAMA3, and PCSK2 with myocardial infarction in Japanese individuals. Atherosclerosis. 210:468–473. 2010. View Article : Google Scholar : PubMed/NCBI
13.	Itoh Y, Mizuki N, Shimada T, et al: High-throughput DNA typing of HLA-A, -B, -C, and -DRB1 loci by a PCR-SSOPLuminex method in the Japanese population. Immunogenetics. 57:717–729. 2005. View Article : Google Scholar : PubMed/NCBI
14.	Benjamini Y and Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B. 57:289–300. 1995.
15.	Warshawsky I and Schwartz AL: The 39-kDa protein regulates LRP activity in cultured endothelial and smooth muscle cells. Eur J Cell Biol. 69:156–165. 1996.PubMed/NCBI
16.	Lupu F, Heim D, Bachmann F and Kruithof EK: Expression of LDL receptor-related protein/alpha 2-microglobulin receptor in human normal and atherosclerotic arteries. Arterioscler Thromb. 14:1438–1444. 1994. View Article : Google Scholar : PubMed/NCBI
17.	Handschug K, Schulz S, Schnürer C, et al: Low-density lipoprotein receptor-related protein in atherosclerosis development: up-regulation of gene expression in patients with coronary obstruction. J Mol Med. 8:596–600. 1998. View Article : Google Scholar
18.	González P, Alvarez R, Reguero JR, et al: Variation in the lipoprotein receptor-related protein, alpha2-macroglobulin and lipoprotein receptor-associated protein genes in relation to plasma lipid levels and risk of early myocardial infarction. Coron Artery Dis. 13:251–254. 2002.
19.	Hörlein AJ, Näär AM, Heinzel T, et al: Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature. 377:397–404. 1995.PubMed/NCBI
20.	Chen JD and Evans RM: A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature. 377:454–457. 1995. View Article : Google Scholar : PubMed/NCBI
21.	Zamir I, Zhang J and Lazar MA: Stoichiometric and steric principles governing repression by nuclear hormone receptors. Genes Dev. 11:835–846. 1997. View Article : Google Scholar : PubMed/NCBI
22.	Dormandey J, Charbonnel B, Eckland DJ, et al: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet. 366:1270–1289. 2005.
23.	Nissen SE, Nicholls SJ, Wolski K, et al: Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 299:1561–1573. 2008. View Article : Google Scholar : PubMed/NCBI
24.	Newton JL, Allen A, Westley BR and May FE: The human trefoil peptide, TFF1, is present in different molecular forms that are intimately associated with mucus in normal stomach. Gut. 46:312–320. 2000. View Article : Google Scholar : PubMed/NCBI
25.	Katoh M: Trefoil factors and human gastric cancer (Review). Int J Mol Med. 12:3–9. 2003.